Top News

Allergan Buys MAP Pharmaceuticals




Irvine-based Allergan and MAP Pharmaceuticals said this morning that Allergan has agreed to acquire MAP Pharmaceuticals, in a deal worth approximately $958M. Allergan said it will pay $25.00 per share for publicly held MAP Pharmaceuticals. MAP Pharmaceuticals develops biopharmaceuticals, with its lead product being LEVADEX, an orally inhaled drug under trials for treating migraines in adults.


 

Marketplace


 

 

Latest Headlines

Browse Issues

 
 

Keep up with all of the latest Southern California high tech news via email (it's free!)



or Cancel